# QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension

> **NCT06716970** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Wuhan Createrna Science and Technology Co., Ltd** · enrollment: 810 (estimated)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** QR12000 75mg
- **DRUG:** QR12000 75mg placebo
- **DRUG:** QR12000 150mg
- **DRUG:** QR12000 150mg placebo
- **DRUG:** Sacubitril/valsartan 200mg
- **DRUG:** Sacubitril/valsartan 200mg placebo

## Key facts

- **NCT ID:** NCT06716970
- **Lead sponsor:** Wuhan Createrna Science and Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-30
- **Primary completion:** 2026-04-30
- **Final completion:** 2027-02-28
- **Target enrollment:** 810 (ESTIMATED)
- **Last updated:** 2024-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06716970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06716970, "QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06716970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*